Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, BCL-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab

Cancer Research

Volumn 64, Issue 19, 2004, Pages 7117-7126

  Jazirehi, Ali R ^a   Vega, Mario I ^a   Chatterjee, Devasis ^a   Goodglick, Lee ^b   Bonavida, Benjamin ^a,c  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; PACLITAXEL; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN RAF 1 KINASE INHIBITOR; RAF PROTEIN; RITUXIMAB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BINDING AFFINITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DAUDI CELL; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

AMINO ACID SEQUENCE; ANDROGEN-BINDING PROTEIN; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; B-LYMPHOCYTES; BCL-X PROTEIN; CELL LINE, TUMOR; DOWN-REGULATION; DRUG SYNERGISM; HUMANS; LYMPHOMA, NON-HODGKIN; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SEQUENCE DATA; PACLITAXEL; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-RAF; UP-REGULATION;

EID: 4944264724     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3500     Document Type: Article

References (46)

1. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-7.
2. Press OW, Applebaum F, Ledbetter JA. Monoclonal 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69:584-91.
3. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45.
4. Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol 2002;29:36-40.
5. Coiffier B. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Semin Oncol 2003;30:21-7.
6. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9.
7. Alas S, Bonavida B. Rituximab inactivates STAT3 activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61:5137-44.
8. xL and Apaf-1 expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003;11:1183-93.
9. Tudor G, Aguilera A, Halverson DO, Laing ND, Sauville EA. Susceptibility to drug-induced apoptosis correlates with differential modulation of Bad, Bcl-2 and Bcl-xL protein levels. Cell Death Differ 2000;7:574-86.
10. Xerri L, Parc P, Brousset P, et al. Predominant expression of the long isoform of Bcl-x (Bcl-xL) in human lymphomas. Br J Hematol 1996;92:900-6.
11. xL can confer a multi-drug resistance phenotype. Blood 1995;86:1903-10.
12. Amundson SA, Myers TG, Scudiero D, et al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 2000;60:6101-10.
13. Pardo OE, Arcaro A, Salerno G, et al. Fibroblast growth factor-2 induces translational regulation of Bcl-xL and Bcl-2 via a MEK-dependent pathway, correlation with resistance to etoposide-induced apoptosis. J Biol Chem 2002;277:12040-6.
14. Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signaling by RKIP. Nature (Lond) 1999;401:173-7.
15. Yeung K, Janosch P, McFerran B, et al. Mechanism of suppression of the Raf/MEK/ extracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein. Mol Cell Biol 2000;20:3079-85.
16. Lee HH, Dadgostar H, Cheng Q, Shu J, Cheng C. NF-κB mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proc Natl Acad Sci USA 1999;96:9136-41.
17. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.
18. Favata MF, Horiuchi KY, Manos EJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32.
19. Tzung SP, Kim CM, Basanez G, et al. Antimycin A mimics a cell death-inducing Bcl-2 homology domain 3. Nat Cell Biol 2001;3:183-91.
20. Lackey KM, Cory R, Davis SV, et al. The discovery of potent c-Raf1 kinase inhibitors. Bioorg Med Chem Lett 2000;10:223-8.
21. Jazirehi AR, Ng C-P, Gan X-H, Schiller G, Bonavida BB. Adriamycin sensitized the Adriamycin-resistam 8226/Dox40 human multiple myeloma cells to Apo2L/TRAIL-mediated apoptosis. Clin Cancer Res 2001;7:3874-83.
22. Lindmark R, Thoren-Tolling K, Sjoquist J. Binding of immunoglobulins to protein A and immunoglobulin levels in mammalian sera. J Immunol Methods 1983;62:1-13.
23. Nicoletti IG, Migliorati MC, Pagliacci F, Grignani C, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
24. Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory gene products and sensitizes non-Hodgkin's lymphoma and multiple myeloma cells to paclitaxel-induced apoptosis. Mol Cancer Ther 2004;3:71-84.
25. Lee W, Mitchell P, Tijan R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 1987;49:741-52.
26. Berenbaum MC. A method for testing for synergy with any number of agents. J Infect Dis 1978;137:122-30.
27. Scudiero DA, Shoemaker RH, Paull KD, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity using human and other tumor cell lines. Cancer Res 1988;48:4827-33.
28. Berinstein NL, Grillo-Lopei AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998;9:995-1001.
29. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy, 2nd ed. 2. Philadelphia: Lippincott-Raven Publishers; 1996. p. 263.
30. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000;48:673-83.
31. Sevilla L, Zaldumbide A, Pognonec P, Boulukos KE. Transcriptional regulation of the bcl-x gene encoding the anti-apoptotic Bcl-xL protein by Ets. Rel/NF-kB. STAT and AP-1 transcription factor families. Histol Histopathol 2001;16:595-601.
32. Manna SK, Haridus V, Aggrawal BB. Bcl-xL suppresses TNF-mediated apoptosis and activation of nuclear factor-kB, activation protein-1 and c-Jun N-terminal kinase. J Interferon Cytokine Res 2000;20:725-35.
33. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002;99:1314-9.
34. Mathas S, Rickers A, Bommert K, Dorken B, Mapara MY. Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. Cancer Res 2000;60:7170-6.
35. Li SP, Junttila MR, Han J, Kahari VM, Westermarck J. p38 mitogen-activated protein kinase pathway suppresses cell survival by inducing dephosphorylation of mitogen-activated protein/extracellular signal-regulated kinase kinase1/2. Cancer Res 2003;63:3473-7.
36. Chang F, Steelman LS, Lee JT, et al. Signal transduction mediated by the Ras/Raf/ MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia (Baltimore) 2003;17:1263-93.
37. Weinstein-Oppenheimer CR, Henriquez-Roldan CF, Davis JM, et al. Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res 2001;7:2898-907.
38. Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res 2001;7:775-83.
39. Dai Y, Yu C, Sing V, et al. Phramacological inhibitors of the mitogen activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res 2001;61:5106-15.
40. MacKeigan JP, Collins TS, Ting JP-Y. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem 2000;275:38953-6.
41. Yu C, Wang S, Dent P, Grants S. Sequence dependent potentiation of paclitaxel-mediated apoptosis in human leukemia cells by inhibitin of the mitogen activated protein kinase kinase/mitogen activated protein kinase pathway. Mol Pharmacol 2001;60:143-54.
42. Jacobs-Heller SM, Wickrema A, Birrer MJ, Sawyer ST. AP-1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol Cell Biol 1998;18:3699-707.
43. Claude Chan HT, Hughes D, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480-9.
44. Chatterjee D, Bai Y, Wang Z, et al. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 2004;279:17515-23.
45. Yeung KC, Rose DW, Dhillon AS, et al. Raf kinase inhibitor protein interacts with NF-kappa B-inducing kinase and TAK1 and inhibits NF-kappa B activation. Mol Cell Biol 2001;21:7207-17.
46. Fu Z, Smith PC, Zhang L, et al. Effects of Raf kinase inhibitor protein expression of prostate cancer metastasis. J Natl Cancer Inst (Bethesda) 2003;95:878-89.